Immunotherapy Gone Viral: Bortezomib and oHSV Enhance Antitumor NK-Cell Activity.

Published

Journal Article

Oncolytic viruses, proteasome inhibitors, and natural killer (NK)-cell immunotherapy have all been studied extensively as monotherapies but have never been evaluated in combination. Synergetic treatment of oncolytic virus-infected glioblastomas with a proteasome inhibitor induces necroptotic cell death to enhance NK-cell immunotherapy, prolonging survival against human glioblastoma. Clin Cancer Res; 22(21); 5164-6. ©2016 AACRSee related article by Yoo et al., p. 5265.

Full Text

Duke Authors

Cited Authors

  • Suryadevara, CM; Riccione, KA; Sampson, JH

Published Date

  • November 1, 2016

Published In

Volume / Issue

  • 22 / 21

Start / End Page

  • 5164 - 5166

PubMed ID

  • 27521450

Pubmed Central ID

  • 27521450

International Standard Serial Number (ISSN)

  • 1078-0432

Digital Object Identifier (DOI)

  • 10.1158/1078-0432.CCR-16-1666

Language

  • eng

Conference Location

  • United States